ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patterns in expressed proteins. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.…
Stockholmsbörsen faller – AI-oro pressar verkstad
ExpreS2ion Biotech Holding (STO: EXPRS2) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 19 employees.
The shares were at 0.8200 SEK on 20 November 2026, down 95.7% over 52 weeks. Its 52-week range is 0.6100 SEK to 19.40 SEK: the price is 95.8% below the high and 34.4% above the low.
Its market capitalisation is 32.36M SEK.
ExpreS2ion Biotech Holding reports return on equity of -106.7%, an operating margin of -180.8% and revenue up 237.7% year over year.
It holds more cash than debt, a net cash position of 32.93M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 February 2027.